Key result
Erythropoietin and IV iron reduce CHF deaths by ~25% absolute while improving hospitalizations.
Why the study?
Although mild anemia occurs frequently in patients with CHF, there is very little information about the effect of correcting it with erythropoietin and intravenous iron.
Does subcutaneous erythropoietin and intravenous iron improve cardiac function, renal function, and hospitalization in patients with severe congestive heart failure and mild anemia?
RCT (n=32)
randomized
Does subcutaneous erythropoietin and intravenous iron improve cardiac function, renal function, and hospitalization in patients with severe congestive heart failure and mild anemia?
Absolute Event Rate: 0% vs 25%
Treating mild anemia with erythropoietin and intravenous iron in patients with severe, resistant heart failure significantly improves cardiac function, renal function, and reduces hospitalizations.
No takes yet. Share an insight, caveat, or question.
Supports treating mild anemia with erythropoietin and iron in severe resistant heart failure; extends randomized evidence for anemia correction improving outcomes.
Silverberg et al. (2001) conducted an RCT in severe congestive heart failure and mild anemia (n=32). Subcutaneous erythropoietin and intravenous iron vs. No treatment for anemia was evaluated on Death from CHF-related illnesses. Subcutaneous erythropoietin and intravenous iron for mild anemia in severe congestive heart failure reduced CHF-related deaths (0% vs 25%) and improved cardiac function and hospitalization rates.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: